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CASE REPORT
Pseudomembranous colitis in four patients with cystic fibrosis
following lung transplantation
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Pseudomembranous colitis is an uncommon complication in
patients with cystic fibrosis, despite the use of multiple high-
dose antibiotic regimens and the frequency of hospital
admissions. Four patients from a total of 137 patients with
cystic fibrosis undergoing lung transplantation are described
who developed fulminant pseudomembranous colitis. Initial
presentation was variable and the mortality rate was 50%
despite urgent colectomy. In one case the presenting abdominal
distension was thought to be due to meconium ileus equivalent.
It is concluded that Clostridium difficile colitis may be a difficult
diagnosis in patients with cystic fibrosis and follows a fulminant
course after lung transplantation.
C
lostridium difficile colitis is rare in patients with cystic
fibrosis (CF), although asymptomatic carriage has been
reported to occur in up to 50%.1 2 We describe four
patients who developed severe pseudomembranous colitis with
variable presentation following lung transplantation with
significant morbidity and mortality. The role of CT scanning
in diagnosis is discussed.
CASE REPORTS
Case 1
Two months after lung transplantation, a 22-year-old man with
CF was treated for acute allograft rejection and pulmonary
infection with steroids and antibiotics. He initially received
piperacillin-tazobactam which was subsequently changed to
flucloxacillin after 48 h following culture of Staphylococcus aureus
from bronchoalveolar lavage fluid. His respiratory status
improved over the following days but he developed abdominal
pain, constipation and a palpable mass in the right iliac fossa. A
clinical diagnosis of meconium ileus equivalent was made, a
condition he had experienced previously. He was treated with
gastrograffin and had a good bowel movement later that day.
Although his symptoms initially settled, he developed further
pain 3 days later with associated diarrhoea and a neutrophil
leucocytosis. An abdominal radiograph showed thickened large
bowel with very little luminal gas. A CT scan of the abdomen
confirmed gross thickening of the entire colon consistent with
severe pseudomembranous colitis (fig 1). Stool analysis
confirmed C difficile toxin. Metronidazole was commenced
but, because of the high risk of perforation, a subtotal
colectomy was performed. Severe pseudomembranous colitis
was confirmed on histopathological examination. He made an
uneventful recovery.
Case 2
Ten years after lung transplantation for CF, a 32-year-old
woman developed neutropenic sepsis and renal failure. She
was commenced on intravenous piperacillin-tazobactam
and continuous venovenous haemofiltration. Although she
had diarrhoea, the stool was negative for C difficile toxin. A CT
scan of the abdomen showed thickening of the colon.
Flexible sigmoidoscopy with biopsies failed to show any
evidence of infection or colitis. She improved over the next
3 days but then developed profuse diarrhoea and a neutrophil
leucocytosis. A presumptive diagnosis of pseudomembranous
colitis was made and metronidazole commenced. Stool
analysis subsequently confirmed C difficile and she gradually
improved.
Case 3
A 28-year-old man with CF underwent lung transplantation
and received aztreonam and clindamycin. His initial post-
operative course was complicated by reperfusion injury requir-
ing reintubation and renal failure. He developed abdominal
distension and initially a clinical diagnosis of meconium ileus
equivalent was made. Abdominal radiography showed a grossly
dilated large bowel and a manual evacuation was performed.
The following day he became septic and hypotensive and
antimicrobial treatment was changed to piperacillin-tazobac-
tam and fluconazole in the light of bronchoalveolar lavage
culture. A laparotomy was performed on the suspicion of
perforation. No perforation was found but a caecostomy was
fashioned to decompress his bowel. At 37 days after transplan-
tation he remained dependent on a ventilator and dialysis but
without further bowel problems and off antibiotics. He
developed right upper abdominal pain; ultrasonography
revealed gallbladder sludge but also a thickened colon
suggestive of colitis. A CT scan confirmed a grossly thickened
large bowel at risk of perforation despite minimal diarrhoea
rectally and only soft stool from his stoma. Piperacillin-
tazobactam, metronidazole and caspofungin were commenced.
Colectomy was delayed as he initially refused consent but by
this time he was deteriorating rapidly with sepsis. He died
1 week following colectomy from multiple organ failure.
Histological examination of the resected colon showed severe
pseudomembranous colitis.
Case 4
A 38-year-old woman with CF underwent lung transplantation,
complicated by early haemodynamic instability followed by
renal failure and failed extubation. She then developed
abdominal distension and diarrhoea, negative for C difficile
toxin. Despite continuing episodes of diarrhoea and distension,
stool toxin remained persistently negative. Bronchoalveolar
lavage isolated Pseudomonas spp and she was commenced on
ciprofloxacin and aztreonam. Diarrhoea, abdominal pain and
distension remained problematic, and a CT scan showed
thickened large bowel consistent with pseudomembranous
colitis. A further stool specimen tested positive for C difficile.
Metronidazole was commenced with resolution of diarrhoea
and negative stool toxin after 5 days. However, her clinical
condition remained critical and she died 42 days after
transplantation from multiorgan failure.
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DISCUSSION
Clostridium difficile is a spore-forming Gram positive bacillus. It
is a well recognised cause of antibiotic-associated diarrhoea.3
Asymptomatic carriage is rare in healthy adults but it is more
frequent during hospitalisation, occurring in up to 25% of
inpatients.2 4 Clostridium difficile colitis results from a chain of
events: first a disruption of bowel flora, followed by colonisa-
tion and finally toxin-mediated mucosal damage and inflam-
mation.4 The clinical symptoms may vary from a mild diarrhoea
to fulminant colitis with severe septic shock (seen in 1–3%).5
Diagnosis is made by the detection of toxins in the stool.
Pseudomembranous colitis, the most severe manifestation of
the disease, presents with diarrhoea, abdominal cramping and
tenderness, with systemic symptoms that may lead to
haemodynamic collapse. Treatment with metronidazole or
vancomycin should be promptly initiated and improvement is
generally seen within 48–72 h.4 Surgical intervention is
mandatory in perforation and may be required in severe cases
where medical treatment is not sufficient or where improve-
ment is not seen.
Carriage rates of C difficile in patients with CF have been
reported to be up to 50%, but despite this and the numerous
courses of antibiotics and hospital admissions these patients
undergo, pseudomembranous colitis remains rare.1 2 6 The first
case was described in 1992 with only a few subsequent
reports.2 6 7 A genotype link (N1303K mutation) has been
described between CF and C difficile,7 although none of our
patients possessed this genotype. To date, although various
hypotheses have been suggested, there is no conclusive
reason to explain the low rates of C difficile in CF.7 8
Pseudomembranous colitis has been described with a high
incidence in patients following lung transplantation by Dallal et
al.3 Their series of 2334 patients with C difficile over an 11 year
period included 78 of 250 lung transplants causing significant
morbidity and mortality.
We describe four cases of severe C difficile colitis in patients
with CF following lung transplantation and illustrate a number
of important points in the diagnosis and management of these
patients. First, the presentation was varied and—particularly in
case 1—was associated initially with an absence of diarrhoea
and signs far more in keeping with meconium ileus equivalent.
Case 3 underwent caecostomy and, despite grossly abnormal CT
appearances of his large bowel, he did not exhibit significant
diarrhoea. Both of these patients went on to have a subtotal
colectomy, early in the course of the illness in case 1 and
delayed following failed medical treatment in case 3. The two
other cases with diarrhoea responded rapidly to metronidazole.
CT scanning played an important role in the management of
these patients in assisting with diagnosis, excluding meconium
ileus equivalent and giving prognostic information regarding
the severity of the disease.
The importance of toxin-negative stool analysis despite
obvious symptoms and extensive radiographic abnormality is
highlighted in cases 2 and 4. Indeed, in case 2, even
sigmoidoscopy after CT scanning revealed negative findings. A
high index of clinical suspicion with close monitoring of the
patient’s condition is required as symptoms and signs may be
misleading and deterioration with haemodynamic collapse
sudden.
Immunosuppression may have played a role in the variable
presentation of the condition and is likely to be important in
the pathogenesis of disease in our cases by increasing the risk of
colonisation, as highlighted by the series of Dallal et al.3
However, the low overall rate of C difficile in our institution
mitigates against this being the sole reason.
Diagnosis is often made difficult in the intubated ventilated
patient because of difficulty in communication. The two
patients on a ventilator both had an early tracheostomy
performed with a speaking valve.
Enteral nutritional support is of great importance in any
critically ill patient for energy provision and maintenance of
enterocyte integrity. All four of our patients received enteral
feeding throughout their illness with either nasogastric feeding
or oral supplementation.
Antibiotics had been administered in the preceding days to
weeks in all patients. Three of the four patients had been
treated with piperacillin-tazobactam shortly before presenta-
tion. Piperacillin-tazobactam is not listed as a common cause of
C difficile colonisation and, in fact, its use in the treatment of
hospital-acquired infections is credited with lowering the
incidence of C difficile.9
In conclusion, we present a series of four patients with CF
who developed severe C difficile colitis following lung trans-
plantation. Two patients died, two required a colectomy, and
the disease was certainly a significant event in the decline of a
further patient. In one case the presentation of the disease was
mistaken for meconium ileus equivalent and in a further case a
diagnosis took several days to secure, highlighting the need for
a high level of clinical suspicion. CT scanning revealed colitis in
all patients; it not only suggested the diagnosis but gave an
important indicator to the severity of the disease. Clostridium
difficile colitis is an uncommon but important diagnosis in
patients with CF following lung transplantation. The persistent
carriage of C difficile in the bowel of prospective transplant
recipients with CF may represent a relative contraindication,
particularly patients with a prior history of pseudomembranous
colitis, and we recommend all lung transplant centres to be
vigilant for this problem.
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Bronchial thermoplasty may improve asthma control up to 12 months after treatment
m Cox G, Thomson NC, Rubin AS. Asthma control during the year after bronchial thermoplasty. N Engl J Med 2007;356:1327–
37
T
his randomised controlled study was designed to assess the efficacy of bronchial
thermoplasty up to 12 months after treatment. Participants had moderate to severe
persistent asthma and were receiving treatment with inhaled corticosteroid and long acting
b agonist (LABA) inhalers. Only patients with worsening asthma control after temporary
withdrawal of the LABA inhaler were eligible for entry. One hundred and twelve subjects were
enrolled; 56 subjects received three treatments of bronchoscopic thermoplasty over 6 weeks in
addition to their usual treatment. No sham bronchoscopies were administered to the control
group. All subjects were assessed at 3, 6 and 12 months. Assessments at 6 and 12 months were
performed after the withdrawal of LABA inhaler treatment. The primary outcome measure was
the frequency of mild exacerbations.
At 12 months, only the bronchial thermoplasty group showed a significant reduction in mild
exacerbations (0.18 (SD 0.31) per patient per week compared with 0.35 (0.32) at baseline).
Compared with the control group, secondary endpoints including morning peak expiratory flow
rate, asthma quality of life questionnaire score, symptom free days and symptom scores showed
significantly greater improvements. Adverse events were significantly higher in the thermoplasty
group during their 6 weeks of treatment.
The authors conclude bronchial thermoplasty in patients with moderate to severe persistent
asthma results in an improvement in asthma control with benefits persisting at 1 year. This
result was observed after a reduction in asthma maintenance treatment. However, the benefit of
any reduction in the number of mild exacerbations seemed to be outweighed by the side effects
of treatment and duration of hospital stay required for the procedures. It would be interesting to
study the efficacy of bronchial thermoplasty in comparison with stable treatment with inhaled
corticosteroid and LABA inhalers, which may be associated with fewer adverse effects.
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